Natco Pharma Limited
NATCOPHARM · Pharma · NSE
₹864
Current Market Price
Fair Value (DCF)
₹1,055
Discount to FV
+22.1%
Updated just now
YieldIQ Score
57/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
56%
ROE
15.4%
Debt/Equity
0.08
WACC
10.5%
Market Cap
₹15,473 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.5%
Return on capital employed
EV / EBITDA
7.3×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
135.8×
EBIT covers interest
Current Ratio
5.59×
Short-term liquidity
Asset Turnover
0.47×
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.5%
3-year revenue growth
Revenue CAGR (5Y)
19.0%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹863.9
Bear case
Margin of Safety -58.8%
Implied upside -37.0%
Base case
Margin of Safety +15.3%
Implied upside +18.1%
Bull case
Margin of Safety +29.2%
Implied upside +41.3%
Ratio Trends
NATCOPHARM · last 9 annual periods
ROE
15.4%
ROCE
17.5%
Operating Margin
—
Debt / Equity
0.08×
PE
14.1×
EV / EBITDA
9.8×
Historical Financials
NATCOPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1905 Cr | ₹2697 Cr | ₹3979 Cr | ₹4430 Cr | ₹4078 Cr | +21.0% |
| EBITDA | ₹358 Cr | ₹1035 Cr | ₹1872 Cr | ₹2551 Cr | ₹1734 Cr | +48.4% |
| EBIT | ₹220 Cr | ₹876 Cr | ₹1693 Cr | — | — | +66.6% |
| PAT | ₹170 Cr | ₹715 Cr | ₹1388 Cr | ₹1885 Cr | ₹1419 Cr | +70.0% |
| EPS (diluted) | ₹9.32 | ₹39.18 | ₹77.34 | — | — | +69.7% |
| CFO | ₹46.5 Cr | ₹849 Cr | ₹1212 Cr | ₹1697 Cr | ₹1768 Cr | +148.3% |
| CapEx | ₹-243 Cr | ₹-206 Cr | ₹-359 Cr | ₹-512 Cr | ₹-391 Cr | — |
| FCF | ₹-196 Cr | ₹644 Cr | ₹853 Cr | ₹1185 Cr | ₹1377 Cr | — |
| Total Assets | ₹5109 Cr | ₹5657 Cr | ₹6906 Cr | ₹8631 Cr | ₹11.1K Cr | +21.3% |
| Total Debt | ₹432 Cr | ₹176 Cr | ₹371 Cr | ₹279 Cr | ₹714 Cr | +13.4% |
| Shareholders' Equity | ₹4264 Cr | ₹4874 Cr | ₹5853 Cr | ₹7607 Cr | ₹9221 Cr | +21.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NATCOPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 ERIS ERIS | — | — | Pending | 15.9% | 29.0× |
 ASTRAZEN ASTRAZEN | — | — | Pending | 21.5% | 103.5× |
 WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 EMCURE EMCURE | — | — | Pending | 18.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
29 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹30.50/sh
Last payout
2026-02-18
₹1.50
Peak payout
₹7.00
Trailing yield
0.58%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Natco Pharma Limited (NATCOPHARM.NS) trades at 863.90 vs a model fair value of 1055.09, a gap of 22.1%. Piotroski F-score: 6/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NATCOPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NATCOPHARM →
Compare
Head-to-head with peers
Compare NATCOPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NATCOPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.